. Author manuscript; available in PMC: 2013 Sep 1.

Published in final edited form as: Am J Med Genet A. 2012 Aug 7;158A(9):2204–2213. doi: 10.1002/ajmg.a.35532

TABLE II.

Response of Smarcal1^+/+ and Smarcal1^del/del mice to exposure to CPT-11, etoposide and hydroxyurea.

Compound	Dose (mg/kg)	Frequency	Phenotype
Compound	Dose (mg/kg)	Frequency	Smarcal1^+/+	Smarcal1^del/del

CPT-11	40	daily × 56 days	Intermittent diarrhea	Chronic diarrhea, weakness, severe growth arrest
	80	daily × 5 days (1 week rest) daily × 10 days	Weight loss (2:3), mild diarrhea (2:3)	Weight loss (3:3), diarrhea (3:3), severe weakness and death (2:3)

Etoposide	20	daily × 56 days	Normal	Severe growth arrest
	40	daily × 5 days	Weight loss (3:3), severe weakness (2:3), death (1:3)	Weight loss and severe weakness (4:4), death (2:4)

Hydroxyurea	100	daily × 56 days	Normal	Mild growth arrest
	500	daily × 10 days	Weight loss (4:4), death (1:4)	Weight loss (4:4), severe weakness and death (3:4)